HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy

[1]  E. van Marck,et al.  Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival , 2004, Clinical Cancer Research.

[2]  J. Harmey,et al.  Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[3]  P. Vogt,et al.  Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[5]  A. Zeiher,et al.  Akt takes center stage in angiogenesis signaling. , 2000, Circulation research.

[6]  M. Pegram,et al.  Platinum–Taxane Combinations in Metastatic Breast Cancer: An Evolving Role in the Era of Molecularly Targeted Therapy , 2004, Breast Cancer Research and Treatment.

[7]  John Mendelsohn,et al.  Vascular Endothelial Growth Factor Up-regulation via p21-activated Kinase-1 Signaling Regulates Heregulin-β1-mediated Angiogenesis* , 2000, The Journal of Biological Chemistry.

[8]  J. Manivel,et al.  A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. , 2001, The American journal of pathology.

[9]  Louis M. Weiner,et al.  Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format* , 2004, Journal of Biological Chemistry.

[10]  M. Bar‐eli.  Role of Interleukin-8 in Tumor Growth and Metastasis of Human Melanoma , 1999, Pathobiology.

[11]  N. Yorioka,et al.  Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1 , 2004 .

[12]  E. Vitetta,et al.  A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies , 2004, Clinical Cancer Research.

[13]  M. Bar‐eli,et al.  Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. , 2004, European journal of cancer.

[14]  A. Fornace,et al.  p38 MAP kinase's emerging role as a tumor suppressor. , 2004, Advances in cancer research.

[15]  E. Perez,et al.  Future options with trastuzumab for primary systemic and adjuvant therapy. , 2004, Seminars in oncology.

[16]  G. Mills,et al.  Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling* , 2004, Journal of Biological Chemistry.

[17]  D. Ribatti,et al.  Human neuroblastoma cells produce extracellular matrix‐degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo , 1998, International journal of cancer.

[18]  Dihua Yu,et al.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , 2003, Cancer.

[19]  M. Hung,et al.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.

[20]  E. Rofstad,et al.  Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8 , 2002, British Journal of Cancer.

[21]  N. Hynes,et al.  ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.

[22]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[23]  Yosef Yarden,et al.  Signal transduction and oncogenesis by ErbB/HER receptors. , 2004, International journal of radiation oncology, biology, physics.

[24]  F. Itoh,et al.  Smad‐dependent GADD45β expression mediates delayed activation of p38 MAP kinase by TGF‐β , 2002 .

[25]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Robert C. Bast,et al.  HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways , 2005, Cell cycle.

[27]  S. Stein,et al.  Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu. , 2004, Clinical breast cancer.

[28]  A. Green,et al.  Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: Identification of interleukin‐8 as a potential regulatory factor in breast tumours , 1997, International journal of cancer.

[29]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[30]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[31]  I. Sargiannidou,et al.  The Role of Thrombospondin-1 in Tumor Progression , 2001, Experimental biology and medicine.

[32]  R. Bast,et al.  The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition* , 2003, Journal of Biological Chemistry.

[33]  R. Hynes,et al.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Kumar,et al.  The role of HER2 in angiogenesis. , 2001, Seminars in oncology.

[35]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[36]  A. Lucas,et al.  IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells , 2003, Oncogene.

[37]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Monilola A. Olayioye,et al.  NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways , 1999, Oncogene.

[39]  M. Hung,et al.  Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis , 1998, Oncogene.

[40]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Esumi,et al.  Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. , 2002, Molecular biology of the cell.

[42]  R. Bast,et al.  Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression* , 2004, Journal of Biological Chemistry.

[43]  R. Finn,et al.  Monoclonal antibody therapy for breast cancer: herceptin. , 2003, Cancer chemotherapy and biological response modifiers.

[44]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[45]  W. Muller,et al.  ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. , 2005, Biochemical and biophysical research communications.